Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher M Booth

Showing results (61-70 of 349) with videos related to

Pageof 35
Sort By:
JAMA Oncology|March 10, 2022
Biased Evaluation in Cancer Drug Trials-How Use of Progression-Free Survival as the Primary End Point Can MisleadIan F Tannock, Gregory R Pond, Christopher M Booth
Bladder Cancer (Amsterdam, Netherlands)|July 5, 2016
The Role of Population-Based Observational Research in Bladder CancerAndrew G Robinson, Jason P Izard, Christopher M Booth
European Journal of Cancer (Oxford, England : 1990)|June 17, 2014
Disease-free survival as an end-point in the treatment of solid tumours--perspectives from clinical trials and clinical practiceAndrew G Robinson, Christopher M Booth, Elizabeth A Eisenhauer
Journal of General Internal Medicine|July 12, 2023
The Changing Medical Publishing Industry: Economics, Expansion, and EquityChristopher M Booth, Joseph S Ross, Allan S Detsky
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 12, 2020
Informing Patients About Expected Outcomes: The Efficacy-Effectiveness GapArnoud J Templeton, Christopher M Booth, Ian F Tannock
JAMA|May 20, 2024
Study Participants, Future Patients, and Outcomes That Matter in Cancer Clinical TrialsBrooke E Wilson, Elizabeth A Eisenhauer, Christopher M Booth
Cancer|November 2, 2023
Efficacy-effectiveness gaps in oncology: Looking beyond survivalBrooke E Wilson, Timothy P Hanna, Christopher M Booth
Journal of Pain & Palliative Care Pharmacotherapy|August 3, 2005
Rotation to methadone after opioid dose escalation: How should individualization of dosing occur?Camilla Zimmermann, Dori Seccareccia, Christopher M Booth, et al.
Journal of Oncology Practice|May 22, 2019
Would Regionalization of Systemic Cancer Therapy Improve the Quality of Cancer Care?Michael J Raphael, D Robert Siemens, Christopher M Booth
The Lancet. Oncology|March 3, 2022
Progression-free survival: it is time for a new nameBishal Gyawali, Elizabeth Eisenhauer, Michelle Tregear, et al.
Pageof 35

Showing results (61-70 of 349) with videos related to

Sort By:
Pageof 35
JAMA Oncology|March 10, 2022
Biased Evaluation in Cancer Drug Trials-How Use of Progression-Free Survival as the Primary End Point Can MisleadIan F Tannock, Gregory R Pond, Christopher M Booth
Bladder Cancer (Amsterdam, Netherlands)|July 5, 2016
The Role of Population-Based Observational Research in Bladder CancerAndrew G Robinson, Jason P Izard, Christopher M Booth
European Journal of Cancer (Oxford, England : 1990)|June 17, 2014
Disease-free survival as an end-point in the treatment of solid tumours--perspectives from clinical trials and clinical practiceAndrew G Robinson, Christopher M Booth, Elizabeth A Eisenhauer
Journal of General Internal Medicine|July 12, 2023
The Changing Medical Publishing Industry: Economics, Expansion, and EquityChristopher M Booth, Joseph S Ross, Allan S Detsky
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 12, 2020
Informing Patients About Expected Outcomes: The Efficacy-Effectiveness GapArnoud J Templeton, Christopher M Booth, Ian F Tannock
JAMA|May 20, 2024
Study Participants, Future Patients, and Outcomes That Matter in Cancer Clinical TrialsBrooke E Wilson, Elizabeth A Eisenhauer, Christopher M Booth
Cancer|November 2, 2023
Efficacy-effectiveness gaps in oncology: Looking beyond survivalBrooke E Wilson, Timothy P Hanna, Christopher M Booth
Journal of Pain & Palliative Care Pharmacotherapy|August 3, 2005
Rotation to methadone after opioid dose escalation: How should individualization of dosing occur?Camilla Zimmermann, Dori Seccareccia, Christopher M Booth, et al.
Journal of Oncology Practice|May 22, 2019
Would Regionalization of Systemic Cancer Therapy Improve the Quality of Cancer Care?Michael J Raphael, D Robert Siemens, Christopher M Booth
The Lancet. Oncology|March 3, 2022
Progression-free survival: it is time for a new nameBishal Gyawali, Elizabeth Eisenhauer, Michelle Tregear, et al.
Pageof 35